COMMUNIQUÉS West-GlobeNewswire

RS BioTherapeutics Selected for Presentation at American Thoracic Society’s 2024 Respiratory Innovation Summit
18/03/2024
CUMBERLAND, Md., March 18, 2024 (GLOBE NEWSWIRE) -- RS BioTherapeutics, whose mission is to develop life-changing medicines for the millions of people suffering from diseases characterized by pulmonary inflammation, is [...]
Novonesis will host a conference call regarding 2024 outlook and 2023 pro forma financials on March 21
18/03/2024
Novonesis will host a conference call regarding 2024 outlook and 2023 pro forma financials on March 21 at 9.00am CET. To join the live webcast, please click here . To register and receive access details for the [...]
Novo Nordisk A/S - share repurchase programme
18/03/2024
Bagsværd, Denmark, 18 March 2024 – On 6 February 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
Medigene AG to report full year 2023 financial results on March 28, 2024
18/03/2024
Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will report financial results [...]
Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023
18/03/2024
FREEHOLD, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today [...]
Parexel Announces CEO Succession Plan
18/03/2024
Chief Operating & Growth Officer Peyton Howell to succeed Jamie Macdonald effective May 15, 2024; Mr. Macdonald to retire as CEO and continue on the Board of Directors through Dec. 31, 2024 DURHAM, N.C., March 18, [...]
Inside Information: Additional Positive Data from the Phase 1 Part of the BEXMAB Study in Both Higher-Risk HMA-Failed MDS and r/r AML
18/03/2024
Key highlights Latest readout of the BEXMAB study shows more responding patients and good durability of remission amongst HR HMA-failed MDS patients. 4/5 of the initial Phase 1 HR HMA-failed MDS patients were still [...]
T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel
18/03/2024
Study demonstrates T2Resistance Panel utilization enables faster targeted therapy based on direct-from-blood detection of resistance genes LEXINGTON, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ [...]
Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme
18/03/2024
PharmAla now first company to supply both MDMA and Psilocybin into the Australian Market VANCOUVER, British Columbia, March 18, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) ( [...]
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
18/03/2024
Prescription Drug User Fee Act (“PDUFA”) goal date of November 4, 2024 SCOTTSDALE, Ariz., March 18, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial- [...]
UpHealth Completes Sale of Cloudbreak Health at $180 Million Full Cash Deal
18/03/2024
DELRAY BEACH, Fla., March 18, 2024 (GLOBE NEWSWIRE) -- UpHealth, Inc. (“we,” “our,” “UpHealth,” or the “Company”) (NYSE: UPHL) today announced that it completed its previously announced sale of Cloudbreak Health, LLC (“ [...]
Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine
18/03/2024
TN-401 AAV9-Based Gene Therapy Being Developed to Treat the Underlying Cause of PKP2-associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) PKP2 Gene Replacement Therapy Normalized Heart Rhythms, Reversed [...]
Nanox to Report Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024
18/03/2024
PETAH TIKVA, Israel, March 18, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“ Nanox ” or the “ Company ”), an innovative medical imaging technology company, today announced that it will report its [...]
CEO of Orangetheory Fitness David Long Joins Safety Shot’s Board of Directors
18/03/2024
The results-driven CEO will guide the development and marketing of the world’s very first rapid alcohol detox drink. Long has led Orangetheory Fitness through countless pivotal achievements including the launch of two [...]
Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock
18/03/2024
SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it has exchanged all outstanding shares of its Series B [...]
Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options
18/03/2024
BERKELEY, Calif. and MAINZ, Germany, March 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, [...]
Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
18/03/2024
WALTHAM, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the appointment of Amit [...]
Inovalon Announces Converged Submissions To Support Health Plan Risk Adjustment Programs
18/03/2024
Medicare and Commercial Affordable Care Act Plans Can Easily Deploy New Cloud-Based SaaS Solution to Submit Encounter Data to CMS to Support Their Risk Adjustment Programs, Improve Compliance, and Drive Stronger [...]
Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024
18/03/2024
DURHAM, N.C., March 18, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will [...]

Pages